Research of SORD-CMT Natural History and Epalrestat Treatment (SORD-CMT)

Inclusion Criteria: Genetically confirmed SORD-CMT2 patients. Male or non-pregnant, non-lactating female patients, aged > 14 and ≤ 50 years old. Rule out secondary peripheral neuropathy (e.g., diabetic peripheral neuropathy) Voluntarily participate in clinical trials, sign informed consent, and be able to understand and abide by research procedures. P.S. Patients who have a strong willingness to treat and voluntarily purchase epalrestat for treatment (50mg, three times a day) are included in the treatment group. Exclusion Criteria: Presence of any other cause of peripheral neuropathy. Subjects with other neurological disorders affecting the evaluation of study treatment. History of clinically significant unstable medical disease that may cause harm to subjects participating in this study within the past 1 year. Patients with major trauma or extremity surgery before enrollment or planned for extremity surgery before completion of follow-up. Patients with previous bilateral ankle stabilization surgery. Patients who were treated with other related drugs in the 3 months before enrollment. Have any history of drug abuse; have a history of alcohol dependence in the past 3 months. Subjects who are positive for syphilis antibody and HIV antibody. Subjects whose chest X-ray and B-ultrasound show tumors. Patients with poor compliance and unable to complete the study follow-up. Patients who do not agree to participate in the study. Other factors are not suitable for inclusion.